August 22, 2017

Rivaroxaban (Xarelto) Effective for Atrial Fibrillation Patients with High Stroke Risk

Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn more, see:

Rivaroxaban as Effective as Warfarin for Stroke Prevention in Atrial Fibrillation

Comment